Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-13
2007-02-13
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S386000, C544S387000
Reexamination Certificate
active
11347768
ABSTRACT:
Compounds of the following formula (I):where A, a, b, R1, R2, R3, R4and R6are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
REFERENCES:
patent: 4258192 (1981-03-01), Okamoto et al.
patent: 5346907 (1994-09-01), Kerwin, Jr. et al.
patent: 5607937 (1997-03-01), Stuerzebecher et al.
patent: 6855715 (2005-02-01), Liebeschuetz et al.
patent: 739 866 (1996-10-01), None
patent: 1334705 (1973-10-01), None
patent: WO 92 /08709 (1992-05-01), None
patent: WO 94/18185 (1994-08-01), None
patent: WO 98/56771 (1998-12-01), None
CAS Registry Nos. # 871214-81-2 and 851622-18-9 and 850017-14-0 obtained from Aurora Fine Chemicals, Feb. 22, 2006.
CAS Registry Nos. # 871214-81-2 and 851622-18-9 and 850017-14-0 obtained from Enamine, Jan 24, 2006.
CAS Registry Nos. # 851622-18-9 and 850017-14-0 obtained from Ambinter, Jul. 3, 2005.
CAS Registry Nos., pp. 1-18 obtained from Com Genex Product List, published Jun. 26, 2003.
ComGenex Product List (2001), Supplementary information concerning Ten Products available for sale.
Dullweber, F. et al., “Factorising Ligand Affinity: A Combined Thermodynamic and Crystallographic Study of Trypsin and Thrombin Inhibition,”J. Mol. Biol.313 : 593-614, 2001.
Folts et al., “Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Aspirin,”Circulation54(3):365-370, 1976.
Gachet et al., “Purinoceptors on Blood Platelets: Further Pharmacological and Clinical Evidence to Suggest the Presence of Two ADP Receptors,”British Journal Haematology91(2):434-444, Oct. 1995.
Herbert et al., “Clopidogrel, A Novel Antiplatelet and Antithrombotic Agent,”Cardiovascular Drug Reviews11(2):180-198, 1993.
Humphries et al., “Pharmacological Profile of the Novel P2T-Purinoceptor Antagonist, FPL 67085 in vitro and in the Anaesthetized Rat in vivo,”British Journal of Pharmacology115(6):1110-1116, Jul. 1995.
Kamm, W. et al., “Transport of Peptidomimetic Thrombin Inhibitors with a 3-Amidino-Phenylalanine Structure: Permeability and Efflux Mechanism in Monolayers of a Human Intestinal Cell Line (Caco-2),”Pharmaceutical Research18(8): 1110-1118, 2001.
Kaslow and Marsh, “Substituted Bromoquinolines” J. Organic Chemistry 12(3):456-458, May 1947.
Mills, “ADP Receptors on Platelets,”Thrombosis Haemostasis76(6):835-856, Dec. 1996.
Mustard et al., “Isolation of Human Platelets from Plasma by Centrifugation and Washing,”Methods Enzymology169:3-11, 1989.
Pierce, A.C. and Jorgensen, W.L., “Estimation of Binding Affinities for Selective Thrombin Inhibitors via Monte Carlo Simulations,”J. Med. Chem.44 : 1043-1050, 2001.
Späth, “Zur Konstitution der Kynurensäure,”Monatshefte für Chimie42:89-95, 1921.
Bryant Judi A
Buckman Brad O
Islam Imadul
Mohan Raju
Morrissey Michael M
Bernhardt Emily
Schering Aktiengesellschaft
Seed IP Law Group PLLC
LandOfFree
Platelet adenosine diphosphate receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platelet adenosine diphosphate receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platelet adenosine diphosphate receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3876279